OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
SABS
SAB Biotherapeutics, Inc.
There isn't enough reported data to score SABS yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
SABS Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Unavailable |
SABS's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
SABS PE Valuation
SABS has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
SABS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect SABS's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the stronger earnings trend. Trailing diluted EPS is up 147% for OSCR versus SABS down 150%.
SABS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$3.09 | +$3.10 |
| Q2 2025 | -$4.00 | +$2.07 |
| Q1 2025 | -$3.70 | +$2.98 |
| Q4 2024 | -$3.68 | +$3.96 |
| Q3 2024 | -$6.19 | -$0.46 |
| Q2 2024 | -$6.07 | +$0.26 |
| Q1 2024 | -$6.68 | -$0.65 |
| Q4 2023 | -$7.64 | -$3.31 |
SABS is still losing money, but far less than before: $3.09 per share over the past year, against $9.10 at its worst in early 2022.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the stronger quarterly revenue trend. Revenue is up 72% for OSCR versus down 62% for SABS.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
SABS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2024 | $114.7K | -62% |
| Q2 2024 | $263.1K | +208% |
| Q1 2024 | $944.6K | +63% |
| Q4 2023 | $305K | -86% |
| Q3 2023 | $1.3M | -65% |
| Q2 2023 | $85.5K | -99% |
| Q1 2023 | $581.1K | -95% |
| Q4 2022 | $2.2M | -80% |
SABS's revenue has slid since its 2022 peak: $114,698 last quarter, down 62% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2024 | -8726% | -2538 points |
| Q2 2024 | -3877% | +3696 points |
| Q1 2024 | -1206% | +68 points |
| Q4 2023 | -6188% | -5824 points |
| Q3 2023 | -420% | -203 points |
| Q2 2023 | -7573% | -7470 points |
| Q1 2023 | -1274% | -1217 points |
| Q4 2022 | -364% | -297 points |
SABS's operating margin was −8726% last quarter, down 8306 points from the same quarter a year ago, near the bottom of its range since 2021.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the stronger cash trend. Its trailing FCF is up 545% versus its history, compared with SABS at down 97%.
SABS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2024 | -$9.6M | +$3.9M |
| Q3 2024 | -$6.4M | -$1.1M |
| Q2 2024 | -$7.8M | -$2.8M |
| Q1 2024 | -$10.9M | -$9.3M |
| Q4 2023 | -$13.5M | -$11.8M |
| Q3 2023 | -$5.3M | +$3M |
| Q2 2023 | -$4.9M | +$900.1K |
| Q1 2023 | -$1.6M | +$10M |
SABS has burned cash in almost every quarter: −$51M over the past year, against −$39M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over SABS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
SABS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +17% | +13.5M shares |
| 1 year | +903% | +83.9M shares |
| 3 years | +1750% | +88.2M shares |
| 5 years | +37195% | +93M shares |
SABS has 93M diluted shares, up 903% from a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
SABS Net Leverage
SABS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
SABS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.1 | Neutral |
| Stochastic | 46.0 | Neutral |
SABS's weekly RSI is 45 (neutral) and its Stochastic is 46 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
SABS PE vs Healthcare Sector
| Metric | SABS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SABS has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over SABS on trend strength, trading above more of its moving averages.
SABS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.01 | 2.3% above |
| 20 week MA | $3.41 | 9.7% below |
| 50 week MA | $3.66 | 16% below |
| 100 week MA | $3.02 | 2% above |
| 200 week MA | $4.35 | 29% below |
SABS's trend is mixed: it's above two of its five weekly moving averages, and 29% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over SABS on returns for 2026, with the stronger performance.
SABS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $102.1 | $87.5 | -14% |
| 2022 | $87.5 | $6.90 | -92% |
| 2023 | $6.90 | $6.88 | -0.3% |
| 2024 | $6.88 | $4.18 | -39% |
| 2025 | $4.18 | $3.78 | -9.6% |
| 2026 YTD | $3.78 | $3.08 | -19% |
SABS has finished every year since 2021 lower, and it's down 19% so far in 2026.